

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1760R1Serial No.  
09/602,800

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Agus et al.Filing Date  
23 Jun 2000Group  
1614 1642

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
ALH	99 4,753,894	28.06.88	Frankel et al.			
ALH	100 4,935,341	19.06.90	Bargmann et al.			
ALH	101 4,943,533	24.07.90	Mendelsohn et al.			
ALH	102 4,975,278	04.12.90	Senter et al.			
ALH	103 5,169,774	08.12.92	Frankel et al.			
ALH	104 5,288,477	22.02.94	Bacus, S.			
ALH	105 5,359,046	25.10.94	Capon et al.			
ALH	106 5,367,060	22.11.94	Vandlen et al.			
ALH	107 5,401,638	28.03.95	Carney et al.			
ALH	108 5,464,751	07.11.95	Greene et al.			
ALH	109 5,578,482	26.11.96	Lippman et al.			
ALH	110 5,604,107	18.02.97	Carney et al.			
ALH	111 5,663,144	02.09.97	Greene et al.			
ALH	112 5,677,171	14.10.97	Hudziak et al.			
ALH	113 5,705,157	06.01.98	Greene, M. L.			
ALH	114 5,720,937	24.02.98	Hudziak et al.			
ALH	115 5,720,954	24.02.98	Hudziak et al.			
ALH	116 5,725,856	10.03.98	Hudziak et al.			
ALH	117 5,726,023	10.03.98	Cheever et al.			
ALH	118 5,728,687	17.03.98	Bissery, M.			
ALH	119 5,747,261	05.05.98	King et al.			
ALH	120 5,770,195	23.06.98	Hudziak et al.			
ALH	121 5,772,997	30.06.98	Hudziak et al.			
ALH	122 5,776,427	07.07.98	Thorpe et al.			
ALH	123 5,801,005	01.09.98	Cheever et al.			
ALH	124 5,834,229	10.11.98	Vandlen et al.			
ALH	125 5,837,243	17.11.98	Deo et al.			
ALH	126 5,837,523	17.11.98	Greene et al.			
ALH	127 5,840,525	24.11.98	Vandlen et al.			
ALH	128 5,846,538	08.12.98	Cheever et al.			
ALH	129 5,856,110	05.01.99	Vandlen et al.			
ALH	130 5,859,206	12.01.99	Vandlen et al.			
ALH	131 5,869,445	09.02.99	Cheever et al.			
ALH	132 5,876,712	02.03.99	Cheever et al.			
ALH	133 5,877,305	02.03.99	Huston et al.			
ALH	134 5,908,835	01.06.99	Bissery, M.			

Examiner

Diane L. Anderson

Date Considered

4/15/2003

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1760R1Serial No.  
09/602,800

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Agus et al.Filing Date  
23 Jun 2000Group  
1614 1642

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
ALH	135	5,910,486	08.01.99	Curiel et al.		
ALH	136	5,922,845	13.07.99	Deo et al.		
ALH	137	5,939,531	17.08.99	Wels et al.		
ALH	138	5,968,511	19.10.99	Akita et al.		
ALH	139	5,977,322	02.11.99	Marks et al.		
ALH	140	5,985,553	16.11.99	King et al.		
ALH	141	6,015,567	18.01.00	Hudziak et al.		
ALH	142	6,028,059	22.02.00	Curiel et al.		
ALH	143	6,054,297	25.04.00	Carter et al.		
ALH	144	6,054,561	25.04.00	Ring		
ALH	145	6,096,873	01.08.00	Schaefer et al.		
ALH	146	6,123,939	26.09.00	Shawver et al.		
ALH	147	6,165,464	26.12.00	Hudziak et al.		

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
ALH	148	0,616,812 A1	28.09.94	EPO		
ALH	149	711,565	26.08.98	EPO		
ALH	150	2,761,543B2	04.06.98	JAPAN (TRANSLATION ATTACHED)		
ALH	151	2,895,105B2	24.05.99	JAPAN (ENGLISH ABSTRACT AND CLAIMS)		
ALH	152	3-240498	25.10.91	JAPAN (ENGLISH ABSTRACT ATTACHED)		
ALH	153	5-117165	14.05.93	JAPAN (ENGLISH ABSTRACT ATTACHED)		
ALH	154	5-170667	09.07.93	JAPAN (ENGLISH ABSTRACT ATTACHED)		
ALH	155	5-213775	24.08.93	JAPAN (ENGLISH ABSTRACT ATTACHED)		
ALH	156	5-317084	03.12.93	JAPAN (ENGLISH ABSTRACT ATTACHED)		
ALH	157	7-59588	07.03.95	JAPAN (ENGLISH ABSTRACT ATTACHED)		
ALH	158	95,006,982B2	30.01.95	JAPAN (ENGLISH ABSTRACT AND CLAIMS)		
ALH	159	WO 00/61185	19.10.00	PCT		
ALH	160	WO 89/06692	27.07.89	PCT		
ALH	161	WO 92/10573	25.06.92	PCT		
ALH	162	WO 92/20798	26.11.92	PCT		
ALH	163	WO 93/12220	24.06.93	PCT		
ALH	164	WO 93/21232	28.10.93	PCT		
ALH	165	WO 93/21319	28.10.93	PCT		
ALH	166	WO 94/28127	08.12.94	PCT		
ALH	167	WO 95/16051	15.06.95	PCT		

Examiner

Anne L. Holliman

Date Considered

4/25/2003

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1760R1

Serial No.

09/602,800

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Agus et al.

Filing Date

23 Jun 2000

Group

1614 1642

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	No
ALH	168	WO 95/17507	29.06.95	PCT			
ALH	169	WO 95/28485	26.10.95	PCT			
ALH	170	WO 96/18409	20.06.96	PCT			
ALH	171	WO 97/04801	13.02.97	PCT			
ALH	172	WO 97/20858	12.06.97	PCT			
ALH	173	WO 97/27848	07.08.97	PCT			
ALH	174	WO 97/35885	02.10.97	PCT			
ALH	175	WO 97/38731	23.10.97	PCT			
ALH	176	WO 98/02541	22.01.98	PCT			
ALH	177	WO 98/17797	30.04.98	PCT			
ALH	178	WO 98/45479	15.10.98	PCT			
ALH	179	WO 99/31140	24.06.99	PCT			

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ALH	180	Agus et al., "Differential anti-tumor effects of targeting distinct epitopes of the Her-2/neu extracellular domain in xenograft models of prostate cancer" <u>Proceedings of the American Association for Cancer Research Annual Meeting</u> (Abstract #4570) 41:719 (Mar 2000)
ALH	181	Baselga et al., "Anti HER2 Humanized Monoclonal Antibody (Mab) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts" <u>Proceedings of ASCO-13th Annual Meeting</u> (Abstract #53), Dallas, TX 13:63 (Mar 1994)
ALH	182	Baselga et al., "HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications" <u>Oncology</u> 11(3 Suppl 2):43-48 (Mar 1997)
ALH	183	Baselga et al., "Monoclonal antibodies directed against growth factor receptors enhance the efficacy of chemotherapeutic agents" <u>Annals of Oncology</u> (abstract #010) 5(Suppl. 5) (1994)
ALH	184	Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" <u>Cancer Research</u> 58:2825-2831 (July 1998)
ALH	185	Curnow, R., "Clinical experience with CD64-directed immunotherapy. An overview" <u>Cancer Immunology and Immunotherapy</u> 45(3-4):210-215 (Nov-Dec 1997)
ALH	186	Curti, B., "Physical barriers to drug delivery in tumors" <u>Critical Reviews in Oncology-Hematology</u> 14(1):29-39 (Feb 1993)
ALH	187	De Santes et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein" <u>Cancer Research</u> 52:1916-1923 (1992)
ALH	188	DiFiore et al., "erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells" <u>Science</u> 237(4811):178-182 (Jul 10, 1987)
ALH	189	Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" <u>Proc. Natl. Acad. Sci.</u> 83:9129-9133 (1986)
ALH	190	Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Product Directly Mediate Anti-tumor Effects In Vivo" <u>Oncogene</u> 2(4):387-394 (1988)
ALH	191	Ezeh et al., "Differential activation of ErbB receptors in the rat olfactory mucosa by transforming growth factor- $\alpha$ and epidermal growth factor in vivo" <u>Journal of Neurobiology</u> 37(2):199-210 (Nov 5, 1998)

Examiner

Anne L. Halleran

Date Considered

4/25/2003

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1760R1

Serial No.

09/60 800

Applicant

Agus et al.

Filing Date

23 Jun 2000

Group

1614

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ALH	192	Fleiss, JL <u>Statistical Methods for Rates and Proportions</u> , 2nd edition, New York, NY:Wiley pps. 13-17 (1981)
ALH	193	Gemzar (gemcitabine HCL), "Product Information - PDR" (2000)
ALH	194	Green et al., "Preclinical Evaluation of WR-151327: An Orally Active Chemotherapy Protector" <u>Cancer Research</u> 54(3):738-741 (Feb 1, 1994)
ALH	195	Gura, T., "Systems for identifying new drugs are often faulty" <u>Science</u> 278(5340):1041-1042 (Nov 7, 1997)
ALH	196	Guy et al., "Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease" <u>Proc. Natl. Acad. Sci. USA</u> 89(22):10578-10582 (Nov 15, 1992)
ALH	197	Hynes and Stern, "The biology of erbB-2/neu/HER-2 and its role in cancer" <u>Biochimica et Biophysica Acta</u> 1198(2-3):165-184 (Dec 30, 1994)
ALH	198	Ilgen et al., "Characterization of anti-HER/2 antibodies which inhibit the growth of breast tumor cells in vitro" <u>Proceedings of the American Association for Cancer Research</u> (abstract #3209) 37:470 (Mar 1996)
ALH	199	Jain, R., "Barriers to drug delivery in solid tumors" <u>Scientific American</u> 271(1):58-65 (Jul 1994)
ALH	200	James et al., "Phase II trial of the bispecific antibody MDX-H210 (anti-HER2/NEU X anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER2/NEU" <u>Proc. Annu. Meet. Soc. Clin. Oncol.</u> (Abstract No. 1681) 17:436a (1998)
ALH	201	James et al., "Phase II trial of the bispecific antibody MDX-H210 (anti-Her2/Neu X anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinoma that express Her2/Neu" <u>British Journal of Cancer</u> (Abstract #56) 78:19 (1998)
ALH	202	Knox et al., "Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma" <u>Clinical Cancer Research</u> 2(3):457-470 (Mar 1996)
ALH	203	Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" <u>Jpn J. Cancer Res.</u> 80:10-14 (January 1989)
ALH	204	Mendelsohn et al., "Receptor blockade and chemotherapy: a new approach to combination cancer therapy" <u>Annals of Oncology</u> (abstract #040) 7(Suppl. 1):22 (1996)
ALH	205	Myers et al., "Intracellular antibody mediated down-regulation of p185 <sup>erbB-2</sup> expression in malignant prostatic cells" <u>Proceedings of the American Association for Cancer Research Annual Meeting</u> (Abstract #2334) 37:342 (1996)
ALH	206	Nagy et al., "Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy" <u>Pathology Oncology Research</u> 5(4):255-271 (1999)
ALH	207	Norton, L., "Evolving concepts in the systemic drug therapy of breast cancer" <u>Seminars in Oncology</u> 24(4 Suppl 10):S10-3-S10-10 (Aug 1997)
ALH	208	Okabayashi et al., "Podofilox-induced regression of Shope papillomas may be independent of host immunity" <u>Journal of Investigative Dermatology</u> 101(6):852-857 (Dec 1993)
ALH	209	Okuda et al., "The cytostome of Trypanosoma cruzi epimastigotes is associated with the flagellar complex" <u>Experimental Parasitology</u> 92(4):223-231 (Aug 1999)
ALH	210	Pegram et al., "Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers" <u>Oncogene</u> 18:2241-2251 (1999)
ALH	211	Raefsky et al., "Phase II Trial of Docetaxel and Herceptin as First- or Second-Line Chemotherapy for Women with Metastatic Breast Cancer Whose Tumors Overexpress HER2" <u>Proceedings of ASCO</u> (Abstract #523) 18:137a (1999)

Examiner

*Anne C. Holliman*

Date Considered

4/25/2003

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1760R1

Serial No.

09/602 1804

**LIST OF DISCLOSURES CITED BY APPLICANT**

(Use several sheets if necessary)

Applicant

Agus et al.

Filing Date

23 Jun 2000

Group

1614

**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

[illegible]

Examiner

Anne L. Holleran

Date Considered

4/25/2003

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT &amp; TRADEMARK OFFICE

SHEET 1 OF 1  
(REV. 7-80)**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 3118/1J014US1 SERIAL NO: 09/602,800  
APPLICANT: Mark X. Sliwowski FILING DATE: 6/23/00  
CONFIRMATION NO: 1759

**U.S. PATENT DOCUMENTS**

<u>*EXAMINER</u> <u>INITIALS</u>	<u>DOCUMENT</u> <u>NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
-------------------------------------	----------------------------------	-------------	-------------	--------------	-----------------	--------------------

**FOREIGN PATENT DOCUMENTS**

<u>*EXAMINER</u> <u>INITIALS</u>	<u>DOCUMENT</u> <u>NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION</u> <u>YES</u> <u>NO</u>
-------------------------------------	----------------------------------	-------------	----------------	--------------	-----------------	--

**OTHER REFERENCES****(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**

\*EXAMINER  
INITIALS

RH

1. Press Release on Yahoo Finance, May 19, 1998, "Medarex's HER-2 Product Shows Anti-Cancer Effects in Phase II Prostate and Kidney Studies," Medarex, Inc.

EXAMINER:

Anne L. Holliman

DATE CONSIDERED:

4/26/2003

\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 4

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1760R1	Serial No. 09/602,800
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Agus et al.	
		Filing Date 23 Jun 2000	Group 1642

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
Alt	228	2002/0155527	24.10.02	Stuart et al.			
Alt	229	5,514,554	07.05.96	Bacus, S.			
Alt	230	5,571,894	05.11.96	Wels, W. et al.			
Alt	231	5,587,458	24.12.96	King, C. et al.			
Alt	232	5,677,165	14.10.97	de Boer et al.			
Alt	233	5,736,117	07.04.98	Anderson et al.			
Alt	234	5,783,404	21.07.98	Koski, R.			
Alt	235	5,846,749	08.12.98	Slamon et al.			
Alt	236	5,856,089	05.01.99	Wang et al.			
Alt	237	5,925,519	20.07.99	Jensen et al.			
Alt	238	6,270,765	07.08.01	Deo et al.			
Alt	239	6,333,348	25.12.01	Vogel et al.			
Alt	240	6,358,682	19.03.02	Jaffee et al.			
Alt	241	6,395,272	28.05.02	Deo et al.			
Alt	242	6,403,630	11.06.02	Dannenberg et al.			
Alt	243	6,417,168	09.07.02	Greene et al.			
Alt	244	6,458,356	01.10.02	Arakawa et al.			
Alt	245	6,512,097	28.01.03	Marka et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
Alt	246	1,006,194	07.06.00	EPO				
Alt	247	332,865	20.09.89	EPO				
Alt	248	412,116	29.11.95	EPO				
Alt	249	444,181	31.10.01	EPO				
Alt	250	494,135	10.04.96	EPO				
Alt	251	502,812	14.08.96	EPO				
Alt	252	554,441	27.01.99	EPO				
Alt	253	656,267	07.06.95	EPO				
Alt	254	WO 00/61145	19.10.00	PCT				
Alt	255	WO 00/69460	23.11.00	PCT				
Alt	256	WO 00/78347	28.12.00	PCT				
Alt	257	WO 01/00238 A1	04.01.01	PCT				
Alt	258	WO 01/00244 A2	04.01.01	PCT				
Alt	259	WO 01/05425	25.01.01	PCT				
Alt	260	WO 01/09187	08.02.01	PCT				

Examiner

Anne C. Holleran

Date Considered

11/7/2003

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.

Sheet 2 of 4

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Agus et al.		
				Filing Date 23 Jun 2000	Group 1642	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
ALH	261 WO 01/15730	08.03.01	PCT			
ALH	262 WO 01/21192	29.03.01	PCT			
ALH	263 WO 01/32155	10.05.01	PCT			
ALH	264 WO 87/07646	17.12.87	PCT			
ALH	265 WO 89/10412	02.11.89	PCT			
ALH	266 WO 90/14357	29.11.90	PCT			
ALH	267 WO 91/02062	21.02.91	PCT			
ALH	268 WO 91/05264	18.04.91	PCT			
ALH	269 WO 93/03741	04.03.93	PCT			
ALH	270 WO 93/16185	19.08.93	PCT			
ALH	271 WO 96/07321	14.03.96	PCT			
ALH	272 WO 96/16673	06.06.96	PCT			
ALH	273 WO 96/40789	19.12.96	PCT			
ALH	274 WO 97/00271	03.01.97	PCT			
ALH	275 WO 98/02463	22.01.98	PCT			
ALH	276 WO 98/02540	22.01.98	PCT			
ALH	277 WO 98/18489	07.05.98	PCT			
ALH	278 WO 98/33914	06.08.98	PCT			
ALH	279 WO 99/39729	12.08.99	PCT			
ALH	280 WO 99/55367	04.11.99	PCT			
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)						
ALH	281	Ahmed et al., "A New Rapid and Simple Non-Radioactive Assay to Monitor and Determine the Proliferation of Lymphocytes: An Alternative to [ <sup>3</sup> H]Thymidine Incorporation Assay." <u>J. Immunol. Methods</u> 170:211-224 (1994)				
ALH	282	Akiyama et al., "Tumor Promoter and Epidermal Growth Factor Stimulate Phosphorylation of the c-erbB-2 Gene Product in MKV-7 Human Adenocarcinoma Cells" <u>Molecular &amp; Cellular Biology</u> 8(3):1019-1026 (Mar 1988)				
ALH	283	Ahn, Johannes L., "A Target for Phosphoinositide 3-Kinase: Akt/PKB" <u>Trends Biochem. Sci.</u> 20:441-442 (Nov 1995)				
ALH	284	Burden and Yarden., "Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis." <u>Neuron</u> 18(6):847-855 (Jun 1997)				
ALH	285	Curraway et al., "Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2/neu and erbB3" <u>J. Bio. Chem.</u> 270:7111-7116 (Mar 1995)				
ALH	286	Connelly and Stern., "The Epidermal Growth Factor Receptor and the Product of the neu Protooncogene Are Members of a Receptor Tyrosine Phosphorylation Cascade." <u>Proc. Natl. Acad. Sci. USA</u> 87:6054-6057 (Aug 1990)				
ALH	287	Dexmer, G., "Another anniversary for the war on cancer" <u>Biotechnology</u> 12:320 (1994)				
ALH	288	Dillman, R., "Antibodies as cytotoxic therapy" <u>Journal of Clinical Oncology</u> 12(7):1497-1515 (Jul 1994)				
Examiner	Date Considered			11/7/2003		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

USCOMM-DC 80-398.



FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Agus et al.	
				Filing Date 23 Jun 2000	Group 1642
OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)					
289	Goldman et al., "Heterodimerization of the erbB-1 and erbB-2 Receptors in Human Breast Carcinoma Cells: A Mechanism for Receptor Transregulation" <u>Biochemistry</u> 29(50):11024-11028 (1990)				
290	Grauf-Porta et al., "ErbB-2, The Preferred Heterodimerization Partner of All ErbB Receptors, Is a Mediator of Lateral Signaling." <u>EMBO Journal</u> 16(7):1647-1655 (1997)				
291	Grim et al., "erbB-2 knockout employing an intracellular single-chain antibody (scFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells" <u>American Journal of Respiratory Cell &amp; Molecular Biology</u> 15(3):348-354 (Sep 1996)				
292	Jardines et al., "neu(C-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer" <u>Pathobiology</u> 61(5-6):268-282 (1993)				
293	Kannan et al., "CripTo Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells" <u>Journal of Biological Chemistry</u> 272(6):3330-3335 (Feb 7, 1997)				
294	Karunakaran et al., "ErbB-2 is a Common Auxiliary Subunit of NDF and EGF Receptors: Implications for Breast Cancer" <u>EMBO Journal</u> 15(2):254-264 (1996)				
295	Kern et al., "Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody" <u>American Journal of Respiratory Cell &amp; Molecular Biology</u> 9(4):448-454 (Oct 1993)				
296	King et al., "EGF Binding to its Receptor Triggers a Rapid Tyrosine Phosphorylation of the erbB-2 Protein in the Mammary Tumor Cell Line SK-BR-3." <u>EMBO Journal</u> 7(6):1647-1651 (1988)				
297	Kokal et al., "Synergistic Interaction of p185c-neu and the EGF Receptor Leads to Transformation of Rodent Fibroblasts" <u>Cell</u> 58:287-292 (Jul 28, 1989)				
298	Kotté et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-Gamma and Monoclonal Antibodies Directed Against the Extracellular Domain of the Her2/erbB2 Oncogene Protein" <u>FASEB Journal</u> (abstract #1470) 4(7):A1946 (1990)				
299	Kotté et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-gamma and Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" (Program 1470, Joint Mtg of ASEM & AAI in New Orleans, LA on June 4-7, 1990 poster)				
300	Krymskaya et al., "EGF Activates ErbB-2 and Stimulates Phosphatidylinositol 3-Kinase in Human Airway Smooth Muscle Cells." <u>Am. J. Physiol.</u> 276:L246-L255 (1999)				
301	"Could Medarex's NAB be prostate cancer's Herceptin?" <u>Scrip</u> 2442:25 (Jun 2, 1999)				
302	Olayoye et al., "ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent Upon Their Dimerization Partner." <u>Molecular &amp; Cellular Biology</u> 18:5042-5051 (Sep 1998)				
303	Page et al., "A New Fluorometric Assay for Cytotoxicity Measurements In Vitro." <u>Int. J. Oncol.</u> 3:473-476 (1993)				
304	Porrotta and Abuel, "Response of Chronic Relapsing ITP of 10 Years Duration to Rituximab" <u>Blood</u> (Abstract #3360) 92(10 Suppl. 1 Part 1-2):88b (Nov 1998)				
305	Scher et al., "Changing Pattern of Expression of the Epidermal Growth Factor Receptor and Transforming Growth Factor $\alpha$ in the Progression of Prostatic Neoplasms" <u>Clinical Cancer Research</u> 1:545-550 (May 1995)				
306	Sheng et al., "Inhibition of Human Colon Cancer Cell Growth by Selective Inhibition of Cyclooxygenase-2" <u>J. Clin. Invest.</u> 99(9):2254-2255 (May 1997)				
307	Stern and Kamps., "EGF-Stimulated Tyrosine Phosphorylation of p185neu: A Potential Model For Receptor Interactions." <u>EMBO Journal</u> 7(4):995-1001 (1988)				
308	Tan et al., "Heregulin $\beta$ 1-Activated Phosphatidylinositol 3-Kinase Enhances Aggregation of MCF-7 Breast Cancer Cells Independent of Extracellular Signal-Regulated Kinase." <u>Cancer Research</u> 59:1620-1625 (Apr 1999)				
Examiner	Anne L. Holleran		Date Considered	11/7/2003	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

U.S. Dept. of Commerce  
Patent and Trademark Office

**Atty Docket No.**

**F1760R1**

**Serial No.**

09/602,800

### LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

**Applicant**

Agua et al.

Filing Date

23 JUN 2000

**Group**

1642

**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

**Examiner**

Anne L. Holleran

**Date Considered**

11/7/2005

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.

[illegible]